Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens

References

• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.
   PubMed Web of Science ®Google Scholar
• Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673–680.
   PubMed Web of Science ®Google Scholar
• Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361:489–491.
   PubMed Web of Science ®Google Scholar
• Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900–2902.
   PubMed Web of Science ®Google Scholar
• Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004;126:348–354.
   PubMed Web of Science ®Google Scholar
• Ayliffe MJ, Davies FE, de Castro D, et al. Demonstration of changes in plasma cell subsets in multiple myeloma. Haematologica. 2007;92:1135–1138.
   PubMed Web of Science ®Google Scholar
• Brioli A, Giles H, Pawlyn C, et al. Serum free light chain evaluation as a marker for the impact of intra-clonal heterogeneity on the progression and treatment resistance in multiple myeloma. Blood. 2014;123(22):3414–3419.
   PubMed Web of Science ®Google Scholar
• Kuhnemund A, Liebisch P, Bauchmuller K, et al. 'Light-chain escape-multiple myeloma' – an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009;135:477–484.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Rao M, Yu WW, Chan J, et al. Serum free light chain analysis for the diagnosis, management, and prognosis of plasma cell dyscrasias. Rockville (MD): Agency for Healthcare Research and Quality (US). 2012; Report No. 12-EHC102-EF.
   Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075–2085.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063–6073.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210–2221.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28:2612–2624.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827–832.
   PubMed Web of Science ®Google Scholar
• Mori S, Crawford BS, Roddy JV, et al. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. Hematol Oncol. 2012;30:156–162.
   PubMed Web of Science ®Google Scholar
• Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol. 2007;137:240–243.
   PubMed Web of Science ®Google Scholar
• Kumar S, Zhang L, Dispenzieri A, et al. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia. 2010;24:1498–1505.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008;111:4908–4915.
   PubMed Web of Science ®Google Scholar
• Xu Y, Sui W, Deng S, et al. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free kappa to lambda light chains. Leuk Lymphoma. 2013;54:123–132.
   PubMed Web of Science ®Google Scholar
• Khoriaty R, Hussein MA, Faiman B, et al. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clin Lymphoma Myeloma Leuk. 2010;10:E10–E13.
   PubMed Web of Science ®Google Scholar
• Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22:1933–1937.
   PubMed Web of Science ®Google Scholar
• Maltezas D, Dimopoulos MA, Katodritou I, et al. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematol Oncol. 2013;31:96–102.
   PubMed Web of Science ®Google Scholar
• Giarin MM, Giaccone L, Sorasio R, et al. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem. 2009;55:1510–1516.
   PubMed Web of Science ®Google Scholar
• Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29:1627–1633.
   PubMed Web of Science ®Google Scholar
• Iwama K, Chihara D, Tsuda K, et al. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Eur J Haematol. 2013;90:134–141.
   PubMed Web of Science ®Google Scholar
• de Larrea CF, Cibeira MT, Elena M, et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood. 2009;114:4954–4956.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar SK, Dispenzieri A, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013;31:4529–4535.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Paiva B, Lopez-Anglada L, et al. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015;126:858–862.
   PubMed Web of Science ®Google Scholar
• Moustafa MA, Rajkumar SV, Dispenzieri A, et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia. 2015.
   Google Scholar
• Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27:941–946.
   PubMed Web of Science ®Google Scholar